Ibrutinib Intermediate CAS 330792-70-6 Ubunyulu > 98.0% (HPLC)
Igama leMchiza | 5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile |
Izithethantonye | Ibrutinib ePhakathi N-3;3-Amino-5-(4-Phenoxyphenyl)pyrazole-4-Carbonitrile;3-Amino-4-Cyano-5-(4-Phenoxyphenyl)pyrazole;5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile |
Inombolo yeCAS | 330792-70-6 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | I-C16H12N4O |
Ubunzima beMolekyuli | 276.29 |
Ukuxinana | 1.37±0.10 g/cm3 |
I-COA kunye ne-MSDS | Iyafumaneka |
Imvelaphi | Shanghai, China |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | I-Off-White ukuya kwiPowder eKhanyayo etyheli |
Ubunyulu / Indlela yokuHlalutya | >98.0% (HPLC) |
Ilahleko ekomisweni | <1.00% |
Intsalela kwi-Ignition | <0.50% |
Ukungcola ngokupheleleyo | <2.00% |
Iintsimbi ezinzima (njenge Pb) | <20ppm |
I-1 H NMR Spectrum | Ngokungqinelana noLwakhiwo |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Umbindi we-Ibrutinib (CAS: 936563-96-1) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.
I-5-Amino-3- (4-Phenoxyphenyl) -1H-Pyrazole-4-Carbonitrile (CAS: 330792-70-6) iphakathi kwe-Ibrutinib (CAS: 936563-96-1).I-Ibrutinib ibonisa umphumo onamandla kunye nongenakuguquleka we-inhibitory kunye nokukhetha kwi-Btk umsebenzi we-enzymatic.Kwi-BCR indlela ye-DOHH2 ye-cell line, i-Ibrutinib inqanda i-autophosphorylation ye-Btk, i-phosphorylation ye-Btk's physiological substrate PLCγ, kunye ne-phosphorylation ye-downstream kinase, i-ERK kunye ne-IC50 ye-11 nM, i-29 nM kunye ne-13 nM ngokulandelanayo.I-Ibrutinib ibonisa i-dose exhomekeke kwi-dose kunye nexesha elixhomekeke kwi-cytotoxicity kwiiseli ezingapheliyo ze-lymphocytic leukemia (CLL).Ukongeza, i-Ibrutinib ibangela ukufa kweeseli ngokuxhomekeke ekusebenzeni kwendlela ye-caspase kwaye ichasene nokukwazi kweeseli ze-CLL ukuba zande emva kokubonakaliswa kwe-TLR.